Back to Blog
Peptide Policy••9 min read
FDA's Regulatory Shift on Compounded Peptides: What the 2026 Policy Signals Mean for You
A potential FDA regulatory shift on 14 compounded peptides — including BPC-157 and TB-500 — could reshape who gets access to peptide therapy and how. Here's what the current signals actually mean.
PeptIQ Research Team
Editorial
#FDA#Peptide Regulation#policy-2026#compounded-peptides#RFK Jr.#BPC-157#deregulation#TB-500#peptide-access
Track Your Peptide Protocols
Use PeptIQ to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download PeptIQ
